• K E Lafond, R Gharpure, V G Dugan, and E Azziz-Baumgartner.
• Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, 30307, USA. gmj3@cdc.gov.
• Bmc Med. 2023 Jul 27; 21 (1): 273273.

AbstractIn the dynamic landscape of respiratory virus vaccines, it is crucial to assess the value of novel mRNA and combination influenza/COVID-19 vaccines in low- and middle-income countries. Modeling studies, such as the one conducted by Waterlow et al., provide vital information about the cost-benefit potential of these products compared to currently licensed vaccines. However, this approach only accounts for directly measured medically attended influenza-associated illnesses and has two major limitations. First, this method fails to capture the full disease burden of influenza (including non-respiratory and non-medically attended influenza illnesses), which are particularly important drivers of disease burden in infants and older adults. Second, the model does not describe the ancillary benefits of influenza vaccination such as the attenuation of severe disease, prevention of severe non-respiratory outcomes (e.g., myocardial infarctions), or reduced antibiotic use. To obtain a comprehensive understanding of the benefits of influenza vaccines, we must strive to improve the inputs for future modeling-based evaluations.© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

20 keywords...

hide…